fluocinonide has been researched along with Dermatitis Medicamentosa in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aung, PP; Curry, JL; Duke, TC; Glitza Oliva, IC; Ledesma, DA; Marques-Piubelli, ML; Nagarajan, P; Nelson, KC; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA; Wistuba, II | 1 |
| Hanson, M; Petronic-Rosic, V | 1 |
| Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C | 1 |
| Linstrum, J; Skelton, H; Smith, K | 1 |
4 other study(ies) available for fluocinonide and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Topics: Acitretin; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dermatitis; Drug Eruptions; Drug Therapy, Combination; Exportin 1 Protein; Female; Fluocinonide; Glucocorticoids; Humans; Hypertrophy; Immune Checkpoint Inhibitors; Karyopherins; Keratolytic Agents; Lichenoid Eruptions; Melanoma; Programmed Cell Death 1 Receptor; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triamcinolone | 2020 |
Reticulated phototoxic eruption in a patient on long-term diltiazem therapy.
Topics: Administration, Topical; Anti-Inflammatory Agents; Calcium Channel Blockers; Coronary Vasospasm; Dermatitis, Phototoxic; Diltiazem; Drug Eruptions; Fluocinonide; Humans; Hyperpigmentation; Keratinocytes; Male; Middle Aged; Necrosis; Skin | 2008 |
Urticarial hypersensitivity reaction caused by temozolomide.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Eruptions; Eosinophils; Fluocinonide; Histamine H1 Antagonists; Humans; Male; Skin; Temozolomide; Urticaria | 2010 |
Host-vs.-altered-host eruptions in patients on liposomal doxorubicin.
Topics: Acanthosis Nigricans; Administration, Topical; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma; Cytotoxicity, Immunologic; Doxorubicin; Drug Eruptions; Erythema; Female; Fluocinonide; Glucocorticoids; Humans; Keratosis; Liposomes; Middle Aged; Ovarian Neoplasms; Treatment Outcome | 2002 |